Diet control, moderate exercise, behavior modification programs, bariatric surgery and prescription drug treatment are the major interventions used to help people lose weight
While the long-term safety and effectiveness of GLP-1RA for other indications like kidney disease and fatty liver still need verification, attention and research investment in GLP-1RAs for obesity and related conditions are keeping increasing, driving further scientific and medical advancements in metabolic diseases
For patients requiring additional glycaemic control, the dose may be further increased to 1 mg or 2 mg weekly, with at least 4 weeks between dose adjustments
Medicare beneficiaries who are already receiving coverage from their Part D plan for a GLP-1 for a Medicare-covered use, such as type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea, will continue to access the drug through their Part D plan and not through the Medicare GLP-1 Bridge, which will only provide coverage of GLP-1s when used for obesity